Background:Rheumatoid arthritis (RA) and psoriasic arthritis (PsA) are autoimmune diseases, in both diseases it has been described that the main cause of morbidity and mortality is cardiovascular (CV) disease. Dyslipidemia is the most recognized CV risk factor. An association is recognized between the concentrations of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total triglycerides (TG), atherogenic index (AI) and the risk of myocardial infarction (MI), stroke and fatal cardiovascular disease (CVD). The relationship between serum lipid levels and CVD risk is potentially paradoxical in RA but this relationship has not been clarified in PsA.Objectives:To compare lipid profile between groups with RA, PsA and controls.Methods:A cross-sectional observational study was designed, which included 95 patients between 45-75 years who fulfilled the CASPAR classification criteria for PsA. 95 patients between 45-75 years who fulfilled the ACR / EULAR 2010 classification criteria for RA and 95 age-matched controls. Concentrations of CT, HDL-C, LDL-C, TG and atherogenic index were compared between the groups. Clinical measures were compared using one-way ANOVA or Kruskall-Wallis tests. Post-hoc analysis was performed with Bonferroni’s correction. Ap≤ 0.05 was considered statistically significant. The data was analyzed using the SPSS version 25 software package.Results:In our study, no significant difference in LDL-C was found between RA and PsA, however post-hoc analysis was performed where we found higher LDL-C levels among RA patients compared with controls (p0.025). RA patients had higher HDL-C than PsA patients (p0.006) but PsA had a higher HDL-C than controls (p0.007). TC/HDL-C was higher in PsA than RA and controls (p0.050). PsA patients were the group with the lowest HDL-C levels (p0.007). In contrast RA were the groups with the highest HDL-C levels (p0.007). (Table 1).Table 1.Clinical parameters.PARAMETERRAPsAControlspTC*176.6 ± 37.2176.3 ± 35.9186.34 ± 33.1720.089TG**132.7 (102.0-187.3)131.0 (97.2-189.2)118.35(88.2-162.25)0.245HDL-C**50.7 (42.1-62.6)46.7 (37.4-53.9)51.7 (41.3-60)0.007LDL-C*94.36 ± 21.7097.71 ± 30.12105.32 ±31.350.025TC/HDL-C**3.41 (2.81-4.08)3.74 (3.17-4.47)3.49 (2.99-4.52)0.050*Data are reported in mean ± SD**Data is reported in median (IQR)Conclusion:Patients with inflammatory joint diseases have more adverse lipid profiles than controls.References:[1]Pietrzak, A., Chabros, P., Grywalska, E., Kiciński, P., Pietrzak-Franciszkiewicz, K., Krasowska, D., & Kandzierski, G. (2019). Serum lipid metabolism in psoriasis and psoriatic arthritis–an update. Archives of medical science: AMS, 15(2), 369.Disclosure of Interests:None declared
Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial